Correlation Between Landos Biopharma and Cue Biopharma
Can any of the company-specific risk be diversified away by investing in both Landos Biopharma and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Landos Biopharma and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Landos Biopharma and Cue Biopharma, you can compare the effects of market volatilities on Landos Biopharma and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Landos Biopharma with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Landos Biopharma and Cue Biopharma.
Diversification Opportunities for Landos Biopharma and Cue Biopharma
0.43 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Landos and Cue is 0.43. Overlapping area represents the amount of risk that can be diversified away by holding Landos Biopharma and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Landos Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Landos Biopharma are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Landos Biopharma i.e., Landos Biopharma and Cue Biopharma go up and down completely randomly.
Pair Corralation between Landos Biopharma and Cue Biopharma
If you would invest 58.00 in Cue Biopharma on September 12, 2024 and sell it today you would earn a total of 51.00 from holding Cue Biopharma or generate 87.93% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 1.56% |
Values | Daily Returns |
Landos Biopharma vs. Cue Biopharma
Performance |
Timeline |
Landos Biopharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Cue Biopharma |
Landos Biopharma and Cue Biopharma Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Landos Biopharma and Cue Biopharma
The main advantage of trading using opposite Landos Biopharma and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Landos Biopharma position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.Landos Biopharma vs. Apollomics Class A | Landos Biopharma vs. Cardio Diagnostics Holdings | Landos Biopharma vs. Transcode Therapeutics | Landos Biopharma vs. Xenetic Biosciences |
Cue Biopharma vs. Coya Therapeutics, Common | Cue Biopharma vs. Lantern Pharma | Cue Biopharma vs. Fennec Pharmaceuticals | Cue Biopharma vs. Eliem Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Complementary Tools
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |